[{"orgOrder":0,"company":"Anglo-French Drugs and industries","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Nicotinamide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Anglo-French Drugs and industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anglo-French Drugs and industries \/ Lupin","highestDevelopmentStatusID":"12","companyTruncated":"Anglo-French Drugs and industries \/ Lupin"}]

Find Clinical Drug Pipeline Developments & Deals for Niacinamide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The acquisition will strengthen Lupin’s business by adding a portfolio of vitamins, minerals, supplements and neurological products. The acquisition of the AFDIL brands takes Lupin further in shaping its portfolio to emerge as a leading pharmaceutical ...

                          Brand Name : Beplex Forte

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 07, 2022

                          Lead Product(s) : Nicotinamide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved

                          Sponsor : Lupin Ltd

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank